Can-Fite BioPharma (TASE:CANF) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CANF 주식 개요

임상 단계의 바이오 제약 회사인 캔파이트 바이오파마는 이스라엘에서 암, 간 염증성 질환, 발기부전 치료를 위한 경구용 생체 이용 가능한 저분자 치료제를 개발하는 회사입니다.

CANF 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 99.7% 에서 거래

수익은 연간 73.09% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 7.8% 증가했습니다.

위험 분석

최근 3개월간 주가 변동폭 심해

수익이 1백만 달러 미만인 경우 ( $743K )

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( ₪49M )

+ 1 더 많은 위험

Can-Fite BioPharma Ltd. 경쟁사

Evogene

TASE:EVGN

₪50.1m

Kamada

TASE:KMDA

₪1.1b

Univo Pharmaceuticals

TASE:UNVO

₪2.8m

PlantArc Bio

TASE:PLNT

₪6.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Can-Fite BioPharma
과거 주가
현재 주가	₪0.026
52주 최고치	₪0.056
52주 최저치	₪0.025
베타	0.65
11개월 변경	-13.33%
3개월 변경 사항	-23.53%
1년 변경 사항	-21.21%
33년 변화	-85.79%
5년 변화	-89.30%
IPO 이후 변화	-99.92%

최근 뉴스 및 업데이트

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

주주 수익률

	CANF	IL Biotechs	IL 마켓
7D	-3.7%	-0.4%	4.5%
1Y	-21.2%	-18.5%	2.3%

수익률 대 산업: CANF 지난 1년 동안 -18.5 %를 반환한 IL Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: CANF 지난 1년 동안 -0.9 %를 반환한 IL 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is CANF's price volatile compared to industry and market?
CANF volatility
CANF Average Weekly Movement	11.0%
Biotechs Industry Average Movement	7.3%
Market Average Movement	4.3%
10% most volatile stocks in IL Market	7.1%
10% least volatile stocks in IL Market	3.1%

안정적인 주가: CANF 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CANF 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 IL 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1994	8	Motti Farbstein	www.canfite.com

임상 단계의 바이오 제약 회사인 캔파이트 바이오파마는 이스라엘에서 암, 간 염증성 질환, 발기부전 치료를 위한 경구용 생체 이용 가능한 저분자 치료제를 개발하는 회사입니다. 건선 치료를 위한 임상 3상 시험을 완료한 선도 신약 후보물질 피클리데노손을 보유하고 있습니다. 간암 치료제로 임상 3상을 진행 중인 나모데노손, 췌장암 치료제로 임상 2a상, 대사 관련 지방간염 치료제로 임상 2b상, 발기부전 치료제로 전임상 중인 CF602를 개발 중입니다.

Can-Fite BioPharma Ltd. 기본 사항 요약

Can-Fite BioPharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CANF 기본 통계
시가총액	₪53.15m
수익(TTM)	-₪27.48m
수익(TTM)	₪2.49m

21.4x

P/S 비율

-1.9x

P/E 비율

CANF 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CANF 손익 계산서(TTM)
수익	US$667.00k
수익 비용	US$0
총 이익	US$667.00k
기타 비용	US$8.04m
수익	-US$7.37m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0036
총 마진	100.00%
순이익 마진	-1,105.10%
부채/자본 비율	0%

CANF 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CANF 주식 개요

보상

위험 분석

Can-Fite BioPharma Ltd. 경쟁사

TASE:EVGN

₪50.1m

TASE:KMDA

₪1.1b

TASE:UNVO

₪2.8m

TASE:PLNT

₪6.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Recent updates

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate